Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC

Next Previous
Trial Profile

A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afuresertib (Primary) ; FAZ 053 (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Laekna Therapeutics

Most Recent Events

  • 10 Apr 2024 Results ( As of December 11, 2023, n=22) assessing the safety, tolerability, and anti-tumor activity of the combination therapy of LAE005 (PD-L1 antibody) plus afuresertib plus nab-paclitaxel in advanced solid tumors, primarily in TNBC presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 25 Aug 2023 According to a Laekna, Inc. media release, the trial completed the dose escalation phase and determined RP2D and results will be presented as an oral presentation at the Chinese Society of Clinical Oncology (CSCO) 2023 in Xiamen, China in September 2023.
  • 30 May 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top